Niklas Mattsson-Carlgren

Oct 12, 2024 | alzres.biomedcentral.com | Anna Svenningsson |Diana I. Bocancea |Erik Stomrud |Frederik Barkhof |Niklas Mattsson-Carlgren |Sebastian Palmqvist | +3 more

Dec 4, 2023 | jamanetwork.com | Niklas Mattsson-Carlgren |Amsterdam Neuroscience |Brain imaging |Erik Stomrud

Key PointsQuestion  Can plasma biomarkers serve as prescreening tools to identify individuals suitable for treatment with antiamyloid immunotherapies in Alzheimer disease, ie, amyloid β (Aβ)–positive individuals who do not yet have too much tau in the brain? Findings  This cohort study demonstrated the efficacy of using plasma p-tau217 values to both rule out Aβ-negative individuals and identify Aβ-positive individuals who are likely to have high tau burden.

Jul 3, 2023 | n.neurology.org | Claudia Cicognola |Niklas Mattsson-Carlgren |Danielle van Westen |Henrik Zetterberg

AbstractBackground and Objectives Injured pericytes in the neurovascular unit release platelet-derived growth factor β (PDGFRβ) into the CSF. However, it is not clear how pericyte injury contributes to Alzheimer disease (AD)–related changes and blood-brain barrier (BBB) damage. We aimed to test whether CSF PDGFRβ was associated with different AD-associated and age-associated pathologic changes leading to dementia.